BBLGW | Bone Biologics Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	60.50 - 60.50
52 Week Range	0.7000 - 70.44
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2
Average Volume	72
Shares Outstanding	23,820
Market Cap	3,404,638
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2021-10-13

Valuation
Profitability
Growth
Health
P/E Ratio	-420.14
Forward P/E Ratio	N/A
EPS	-0.14
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2
Country	USA
Website	BBLGW

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

BBLGW's peers: IRIX

*Chart delayed

Analyzing fundamentals for BBLGW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see BBLGW Fundamentals page.

Watching at BBLGW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BBLGW Technicals page.